{"id":"https://openalex.org/W2124394654","doi":"https://doi.org/10.1177/0091270008322176","title":"Pharmacokinetics of Amlodipine and Olmesartan After Administration of Amlodipine Besylate and Olmesartan Medoxomil in Separate Dosage Forms and as a Fixed\u2010Dose Combination","display_name":"Pharmacokinetics of Amlodipine and Olmesartan After Administration of Amlodipine Besylate and Olmesartan Medoxomil in Separate Dosage Forms and as a Fixed\u2010Dose Combination","publication_year":2008,"publication_date":"2008-10-30","ids":{"openalex":"https://openalex.org/W2124394654","doi":"https://doi.org/10.1177/0091270008322176","mag":"2124394654","pmid":"https://pubmed.ncbi.nlm.nih.gov/18974285"},"language":"en","primary_location":{"id":"doi:10.1177/0091270008322176","doi":"https://doi.org/10.1177/0091270008322176","is_oa":false,"landing_page_url":"https://doi.org/10.1177/0091270008322176","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035083183","display_name":"Shashank Rohatagi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162815","display_name":"Daiichi Sankyo (United States)","ror":"https://ror.org/055werx92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210104626","https://openalex.org/I4210162815"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Shashank Rohatagi","raw_affiliation_strings":["Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ 08837, USA. srohatagi@dsus.com","Daiichi-Sankyo, Inc., Parsippany, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ 08837, USA. srohatagi@dsus.com","institution_ids":["https://openalex.org/I4210162815"]},{"raw_affiliation_string":"Daiichi-Sankyo, Inc., Parsippany, New Jersey","institution_ids":["https://openalex.org/I4210162815"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100367866","display_name":"James Lee","orcid":"https://orcid.org/0000-0003-4030-1062","observed_orcids":["https://orcid.org/0000-0003-4030-1062"]},"institutions":[{"id":"https://openalex.org/I4210162815","display_name":"Daiichi Sankyo (United States)","ror":"https://ror.org/055werx92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210104626","https://openalex.org/I4210162815"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Lee","raw_affiliation_strings":["Daiichi-Sankyo, Inc., Parsippany, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi-Sankyo, Inc., Parsippany, New Jersey","institution_ids":["https://openalex.org/I4210162815"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108284719","display_name":"Magdy Shenouda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Magdy Shenouda","raw_affiliation_strings":["MDS Pharma Services, Neptune, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MDS Pharma Services, Neptune, New Jersey","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072568604","display_name":"Stephen J. Haworth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162815","display_name":"Daiichi Sankyo (United States)","ror":"https://ror.org/055werx92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210104626","https://openalex.org/I4210162815"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Haworth","raw_affiliation_strings":["Daiichi-Sankyo, Inc., Parsippany, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi-Sankyo, Inc., Parsippany, New Jersey","institution_ids":["https://openalex.org/I4210162815"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018081784","display_name":"Mohinder S. Bathala","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162815","display_name":"Daiichi Sankyo (United States)","ror":"https://ror.org/055werx92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210104626","https://openalex.org/I4210162815"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mohinder Singh Bathala","raw_affiliation_strings":["Daiichi-Sankyo, Inc., Parsippany, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi-Sankyo, Inc., Parsippany, New Jersey","institution_ids":["https://openalex.org/I4210162815"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056118228","display_name":"Mark J. Allison","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Allison","raw_affiliation_strings":["MDS Pharma Services, Phoenix, Arizona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MDS Pharma Services, Phoenix, Arizona","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060329122","display_name":"Igor Rubets","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Igor Rubets","raw_affiliation_strings":["MDS Pharma, Quebec, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MDS Pharma, Quebec, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014478200","display_name":"Reinilde Heyrman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162815","display_name":"Daiichi Sankyo (United States)","ror":"https://ror.org/055werx92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210104626","https://openalex.org/I4210162815"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Reinilde Heyrman","raw_affiliation_strings":["Daiichi-Sankyo, Inc., Parsippany, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi-Sankyo, Inc., Parsippany, New Jersey","institution_ids":["https://openalex.org/I4210162815"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019793347","display_name":"Robert Joseph Noveck","orcid":"https://orcid.org/0000-0002-1059-6405","observed_orcids":["https://orcid.org/0000-0002-1059-6405"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Noveck","raw_affiliation_strings":["MDS Pharma Services, Neptune, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MDS Pharma Services, Neptune, New Jersey","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071455700","display_name":"Daniel E. Salazar","orcid":"https://orcid.org/0000-0002-8081-9280","observed_orcids":["https://orcid.org/0000-0002-8081-9280"]},"institutions":[{"id":"https://openalex.org/I4210162815","display_name":"Daiichi Sankyo (United States)","ror":"https://ror.org/055werx92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210104626","https://openalex.org/I4210162815"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel E. Salazar","raw_affiliation_strings":["Daiichi-Sankyo, Inc., Parsippany, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi-Sankyo, Inc., Parsippany, New Jersey","institution_ids":["https://openalex.org/I4210162815"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5035083183"],"corresponding_institution_ids":["https://openalex.org/I4210162815"],"apc_list":{"value":4150,"currency":"USD","value_usd":4150},"apc_paid":null,"fwci":2.3552,"has_fulltext":false,"cited_by_count":33,"citation_normalized_percentile":{"value":0.89504322,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"48","issue":"11","first_page":"1309","last_page":"1322"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.548799991607666,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.548799991607666,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.18809999525547028,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.09019999951124191,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/amlodipine","display_name":"amlodipine","score":0.9369999766349792},{"id":"https://openalex.org/keywords/olmesartan","display_name":"olmesartan","score":0.9449999928474426},{"id":"https://openalex.org/keywords/olmesartan-medoxomil","display_name":"olmesartan medoxomil","score":0.9990000128746033},{"id":"https://openalex.org/keywords/fixed-dose-combination","display_name":"fixed-dose combination","score":0.9800000190734863},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8399999737739563},{"id":"https://openalex.org/keywords/bioequivalence","display_name":"bioequivalence","score":0.9909999966621399},{"id":"https://openalex.org/keywords/co-administration","display_name":"co-administration","score":0.609000027179718},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.9010000228881836},{"id":"https://openalex.org/keywords/high-fat-meal","display_name":"high-fat meal","score":0.6069999933242798},{"id":"https://openalex.org/keywords/calcium-channel-blockers","display_name":"calcium channel blockers","score":0.7829999923706055},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.9229999780654907}],"concepts":[{"id":"https://openalex.org/C2779766728","wikidata":"https://www.wikidata.org/wiki/Q421156","display_name":"Olmesartan","level":3,"score":0.969562292098999},{"id":"https://openalex.org/C2779646130","wikidata":"https://www.wikidata.org/wiki/Q411347","display_name":"Amlodipine","level":3,"score":0.9431372284889221},{"id":"https://openalex.org/C42404028","wikidata":"https://www.wikidata.org/wiki/Q864940","display_name":"Bioequivalence","level":3,"score":0.8354177474975586},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.792766809463501},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7040226459503174},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5744504928588867},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.5387052297592163},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1772496998310089},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.08362483978271484},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.05862787365913391},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068557","descriptor_name":"Olmesartan Medoxomil","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002121","descriptor_name":"Calcium Channel Blockers","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002121","descriptor_name":"Calcium Channel Blockers","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002121","descriptor_name":"Calcium Channel Blockers","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D013810","descriptor_name":"Therapeutic Equivalency","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017311","descriptor_name":"Amlodipine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017311","descriptor_name":"Amlodipine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D017311","descriptor_name":"Amlodipine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047228","descriptor_name":"Angiotensin II Type 1 Receptor Blockers","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047228","descriptor_name":"Angiotensin II Type 1 Receptor Blockers","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047228","descriptor_name":"Angiotensin II Type 1 Receptor Blockers","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1177/0091270008322176","doi":"https://doi.org/10.1177/0091270008322176","is_oa":false,"landing_page_url":"https://doi.org/10.1177/0091270008322176","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:18974285","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18974285","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W63048433","https://openalex.org/W75245760","https://openalex.org/W1984207528","https://openalex.org/W2017325092","https://openalex.org/W2019755214","https://openalex.org/W2032595010","https://openalex.org/W2037580369","https://openalex.org/W2042282631","https://openalex.org/W2059091590","https://openalex.org/W2088306526","https://openalex.org/W2137408480","https://openalex.org/W2143954917","https://openalex.org/W2163854067","https://openalex.org/W2166981101","https://openalex.org/W3188737672","https://openalex.org/W4237449645"],"related_works":["https://openalex.org/W1760270877","https://openalex.org/W2313337780","https://openalex.org/W2935583499","https://openalex.org/W4221084656","https://openalex.org/W2072251130","https://openalex.org/W2600808827","https://openalex.org/W2736952728","https://openalex.org/W3037278447","https://openalex.org/W3008036297","https://openalex.org/W2976716241"],"abstract_inverted_index":{"The":[0,38,65,95,145],"pharmacokinetics":[1,41],"of":[2,11,42,76,97,131,170,203],"amlodipine":[3,12,43,54,71,87,132,196,217],"and":[4,14,22,44,53,67,72,101,124,133,163,197],"olmesartan":[5,15,45,49,73,91,134,198,204],"in":[6,24,31,211,235],"healthy":[7],"volunteers":[8],"after":[9,74,189,201],"coadministration":[10,234],"besylate":[13],"medoxomil":[16,50,80,92,205],"concomitantly":[17,61],"as":[18],"separate":[19],"dosage":[20],"forms":[21],"together":[23],"a":[25,190,224,236],"fixed-dose":[26,77,182,213,237],"combination":[27,78,183,214],"tablet":[28,184],"were":[29,46,57],"characterized":[30],"5":[32,218],"phase":[33],"I,":[34],"randomized,":[35],"crossover":[36],"studies.":[37],"mean":[39,100],"steady-state":[40],"similar":[47],"when":[48,180],"40":[51,93,209],"mg/day":[52,56],"10":[55,63,81,88,206,221],"administered":[58],"separately":[59],"or":[60],"for":[62,105,140,178],"days.":[64],"total":[66],"maximum":[68,126,165],"exposure":[69,194],"to":[70,86,116,122,155,161,195,208,220,233],"administration":[75,202],"amlodipine/olmesartan":[79],"mg/40":[82],"mg":[83,89,207,210,219],"was":[84,185,199],"bioequivalent":[85],"plus":[90],"mg.":[94,222],"ratio":[96],"least":[98],"squares":[99],"90%":[102],"confidence":[103],"intervals":[104],"the":[106,109,125,137,148,164,175,181,212,227],"area":[107,146],"under":[108,147],"drug":[110,129,149,168],"concentration-time":[111,150],"curve":[112,151],"from":[113,119,152,158],"time":[114,117,120,153,156,159],"zero":[115,121,154,160],"t,":[118,157],"infinity,":[123,162],"observed":[127,166],"plasma":[128,167],"concentration":[130,169],"fell":[135],"within":[136],"prespecified":[138,176],"range":[139],"bioequivalence":[141,179],"(80.0%":[142],"-":[143],"125.0%).":[144],"both":[171],"drugs":[172,229],"also":[173],"met":[174],"criterion":[177],"taken":[186],"30":[187],"minutes":[188],"high-fat":[191],"breakfast.":[192],"Total":[193],"dose-proportional":[200],"formulation":[215],"with":[216],"From":[223],"pharmacokinetic":[225],"perspective,":[226],"2":[228],"are":[230],"well":[231],"suited":[232],"combination.":[238]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}